← All trials
NCT05647954
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 31, 2022
- Primary completion
- Dec 30, 2024
- Completion date
- Jun 30, 2025
- First posted
- Dec 13, 2022
- Last posted
- Dec 13, 2022
- Enrollment
- 350
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Taizhou Hanzhong biomedical co. LTDLead sponsor
- Peking UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.